GLP-1 acts on multiple hypothalamic regions through overlapping but distinct circuits to suppress feeding and regulate body weight.
3 hypothalamic regionsThe arcuate nucleus, paraventricular area, and dorsomedial hypothalamus are the key brain centers where GLP-1 controls hunger
What the researchers found
The review identifies three key hypothalamic nuclei — the arcuate nucleus, paraventricular hypothalamic area, and dorsomedial hypothalamus — as primary targets where GLP-1 signals are integrated to regulate feeding, body weight, and blood sugar. Natural GLP-1, produced by specific neurons in the brainstem (nucleus tractus solitarius), and pharmaceutical GLP-1 receptor agonists engage these circuits through both shared and distinct pathways. The authors highlight that circuit redundancy and context-dependent signaling help explain why GLP-1 drugs produce robust weight loss effects.
Why it matters
GLP-1 drugs like semaglutide and tirzepatide have become blockbuster obesity treatments, but scientists are still uncovering exactly how they suppress appetite in the brain. This review maps out the specific brain circuits involved, which could guide development of next-generation weight loss drugs that target these pathways more precisely with fewer side effects.
How the study worked
This is a narrative review that synthesizes recent research on GLP-1 receptor signaling in hypothalamic feeding circuits. The authors evaluated studies on both endogenous GLP-1 produced by brainstem neurons and pharmacological GLP-1 receptor agonists, proposing a conceptual framework for understanding how these signals are integrated in the brain.
What this study cannot tell us
As a review paper, this study does not present new experimental data. The proposed conceptual framework, while useful for guiding research, has not been fully validated experimentally. Much of the underlying research was conducted in animal models, and the translation to human brain circuits remains an open question.
How to read the evidence
This is a narrative review that synthesizes existing research rather than presenting original experimental data. It provides a useful conceptual framework but relies on the strength of the underlying primary studies.
When this study was published
Published in 2025, this review reflects the most current understanding of GLP-1 brain signaling in the era of widespread GLP-1 drug use for obesity.
The bigger picture
As GLP-1 receptor agonists become the dominant pharmacological approach to obesity, understanding their central nervous system mechanisms is critical. This work fits into a larger effort to move beyond treating GLP-1 drugs as a 'black box' and instead map the precise neural circuits responsible for appetite suppression, which could unlock more targeted therapies.
Questions still open
- Could targeting specific hypothalamic circuits enhance GLP-1 drug efficacy while reducing gastrointestinal side effects?
- How do the brain's responses to natural GLP-1 differ from those triggered by long-acting GLP-1 drugs like semaglutide?
- Does circuit redundancy in the hypothalamus explain why some patients respond better to GLP-1 drugs than others?
Common questions
How does GLP-1 reduce appetite in the brain?
Do GLP-1 drugs work the same way as the body's natural GLP-1?
Read the original research
Glucagon-Like Peptide 1 (GLP-1) Action on Hypothalamic Feeding Circuits.
Endocrinology, 166(10)
Citation
Hwang, Eunsang; Portillo, Bryan; Williams, Kevin W. (2025). Glucagon-Like Peptide 1 (GLP-1) Action on Hypothalamic Feeding Circuits.. Endocrinology, 166(10). https://doi.org/10.1210/endocr/bqaf125